Quantcast

Latest OrbusNeich Stories

2014-06-12 08:28:30

ZWOLLE, The Netherlands, June 12, 2014 /PRNewswire/ -- Randomized Evaluation of short-term DUal antiplatelet therapy in patients with acute coronary syndrome treated with the COMBOTM Dual-Therapy StEnt The Principal Investigators of the REDUCE trial announce the enrolment of the first patient in the REDUCE trial with the OrbusNeich COMBO Dual Therapy Stent at Isala Hospital, Zwolle, the Netherlands. According to the local PI and treating physician, Doctor E....

2014-05-23 04:20:45

COMBO(TM) Dual Therapy Stent shown to actively promote rapid endothelialization and deliver long-term, true vessel healing HONG KONG, May 23, 2014 /PRNewswire/ -- OrbusNeich today announced long-term results from its REMEDEE Trial. In addition to showing that the COMBO(TM) Dual Therapy Stent shows no late target lesion revascularization, the results demonstrate that the stent proactively promotes functional vessel healing. Key findings include: -...

2014-04-24 08:32:29

HONG KONG, April 24, 2014 /PRNewswire/ -- OrbusNeich today announced the appointment of B. Wayne Johnson as president and chief operating officer and the expansion of its board of directors with the additions of Scott Addonizio, vice president & general manager, Shenzhen operations; David Camp, vice president, sales & marketing, Europe, the Middle East and Africa (EMEA); and Christophe Lee, vice president and chief financial officer. Mr. Johnson has more than 32...

2014-04-02 16:31:50

DUBLIN, April 2, 2014 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/znsx2b/global_and ) has announced the addition of the "Global and Chinese Coronary Stent Industry Report 2014" [http://www.researchandmarkets.com/research/znsx2b/global_and ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) The Global and Chinese Coronary Stent Industry Report 2014 is a professional and in-depth study on...

2014-03-28 08:27:19

Post-Market Registry to Evaluate Long-Term Safety and Performance in Routine Practice HONG KONG, March 28, 2014 /PRNewswire/ -- OrbusNeich today announced the completion of enrollment in the prospective, multicenter, all-comers REMEDEE Registry (Multicenter, Prospective, Clinical Outcomes After Deployment of the Abluminal Sirolimus Coated Bio-Engineered Stent (Combo Bio-Engineered Sirolimus Eluting Stent) Post Market Registry) to evaluate the COMBO Stent for the treatment of coronary...

2014-03-25 16:25:35

DUBLIN, Mar. 25, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/k8gx4n/china ) has announced the addition of the "Concise Analysis of the International Interventional Cardiovascular Device Industry" report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769) With the accelerated aging, the prevalence of cardiovascular diseases in China increased year by year. According to statistics of National Health and Family Planning...

2014-02-26 04:21:30

Company Initiates Joint U.S. and Japanese Registration Trial HONG KONG, Feb. 26, 2014 /PRNewswire/ -- OrbusNeich today announced that patient enrollment has been initiated in Japan in the pivotal clinical trial of the COMBO Dual Therapy Stent(TM) (COMBO Stent) employing a single Japan-U.S. protocol conducted as a Global Clinical Trial "proof-of-concept" under the framework of the joint Japan-U.S. Harmonization-By-Doing [HBD] initiative. The first patient was enrolled at Shonan...

2014-02-13 12:27:49

LONDON, Feb. 13, 2014 PRNewswire/ -- Reportbuyer.com just published a new market research report:China Interventional Cardiovascular Device Industry Report, 2013-2015 With the accelerated aging, the prevalence of cardiovascular diseases in China increased year by year. According to statistics of National Health and Family Planning Commission of the People's Republic of China, in 2012 cardiovascular disease deaths in China reached 3.5 million. The fast growing number of heart patients...

2014-01-20 12:25:09

LONDON, Jan. 20, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report: Medical Devices Industry and Market Prospects 2013-2023 Report Details Medical devices - your guide to developments, opportunities, and revenuesWhat does the future hold for medical devices? Visiongain's report shows you potential revenues to 2023, assessing data, trends, opportunities and prospects in this market. Our study gives you revenue forecasts to 2023 at overall world market...


Word of the Day
drawcansir
  • A blustering, bullying fellow; a pot-valiant braggart; a bully.
This word is named for Draw-Can-Sir, a character in George Villiers' 17th century play The Rehearsal.
Related